Bai Jianhao, Wan Zhongqi, Zhou Wanru, Wang Lijun, Lou Wei, Zhang Yao, Jin Haiying
Department of Ophthalmology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Department of Ophthalmology, Shanghai Tenth People's Hospital Affiliated to Tongji University, Tongji University School of Medicine, Shanghai, China.
Front Mol Biosci. 2025 Jan 17;12:1538743. doi: 10.3389/fmolb.2025.1538743. eCollection 2025.
This study aims to perform a comprehensive bibliometric analysis of global research on BRAF and MEK inhibitor resistance in melanoma, identifying key research trends, influential contributors, and emerging themes from 2003 to 2024.
A systematic search was conducted in the Web of Science Core Collection (WoSCC) database to retrieve publications related to BRAF and MEK inhibitor resistance from 1 January 2003, to 1 September 2024. Bibliometric analyses, including publication trends, citation networks, and keyword co-occurrence patterns, were performed using VOSviewer and CiteSpace. Collaborative networks, co-cited references, and keyword burst analyses were mapped to uncover shifts in research focus and global cooperation.
A total of 3,503 documents, including 2,781 research articles and 722 review papers, were analyzed, highlighting significant growth in this field. The United States, China, and Italy led in publication volume and citation impact, with Harvard University and the University of California System among the top contributing institutions. Research output showed three phases of growth, peaking in 2020. Keyword and co-citation analyses revealed a transition from early focus on BRAF mutations and MAPK pathway activation to recent emphasis on immunotherapy, combination therapies, and non-apoptotic cell death mechanisms like ferroptosis and pyroptosis. These trends reflect the evolving priorities and innovative approaches shaping the field of resistance to BRAF and MEK inhibitors in melanoma.
Research on BRAF and MEK inhibitor resistance has evolved significantly. This analysis provides a strategic framework for future investigations, guiding the development of innovative, multi-modal approaches to improve treatment outcomes for melanoma patients.
本研究旨在对全球黑色素瘤中BRAF和MEK抑制剂耐药性的研究进行全面的文献计量分析，确定2003年至2024年的关键研究趋势、有影响力的贡献者和新兴主题。
在Web of Science核心合集（WoSCC）数据库中进行系统检索，以获取2003年1月1日至2024年9月1日期间与BRAF和MEK抑制剂耐药性相关的出版物。使用VOSviewer和CiteSpace进行文献计量分析，包括出版趋势、引文网络和关键词共现模式。绘制合作网络、共被引参考文献和关键词突现分析图，以揭示研究重点的转移和全球合作情况。
共分析了3503篇文献，其中包括2781篇研究论文和722篇综述论文，突出了该领域的显著增长。美国、中国和意大利在出版量和引文影响力方面领先，哈佛大学和加利福尼亚大学系统是贡献最大的机构之一。研究产出呈现三个增长阶段，在2020年达到峰值。关键词和共被引分析显示，研究重点从早期对BRAF突变和MAPK途径激活的关注，转向最近对免疫疗法、联合疗法以及铁死亡和焦亡等非凋亡细胞死亡机制的强调。这些趋势反映了黑色素瘤中BRAF和MEK抑制剂耐药性领域不断变化的优先事项和创新方法。
BRAF和MEK抑制剂耐药性的研究有了显著进展。本分析为未来的研究提供了一个战略框架，指导开发创新的多模式方法以改善黑色素瘤患者的治疗结果。
